<DOC>
	<DOCNO>NCT01783626</DOCNO>
	<brief_summary>Evodial +hemodialyzer consist evolution exist CE mark Evodial device , respect hemodialyzer membrane removal characteristic . Different membrane prototype configuration propose ( 3 version total ) , objective modulate hemodialyzer removal capacity ( convective adsorptive capacity ) . Materials ( include heparin graft specification ) well sterilization process identical Evodial hemodialyzer . Based available preclinical data , clinical study request document vivo different prototype removal capacity respect middle Molecular Weight ( MW ) reference toxin b2 Microglobulin collect data regard protein loss .</brief_summary>
	<brief_title>Evaluation Evodial Hemodialyzer Selectivity Modifications ( Evodial + )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Anuric patient ( diuresis &lt; 300ml ) , 2 . ESRD patient treat least 3 month , 3 . Patient treat HDF postdilution , 4 . Vascular access function properly ( Qb &gt; 250 ml/min ) , 5 . Patient age 18 year , 6 . Written consent participate study ( informed consent ) . 1 . Patient predialytic albuminemia &lt; 3.3 g/dl ( Nephelometry assay ) 2 . Patient know allergy heparin type II heparininduced thrombocytopenia ( HIT type II ) ; 3 . Patient guardianship ; 4 . Women pregnant breast feeding ; 5 . Patient include study could interfere goal current study . 6 . Patient affiliate health system ( beneficiary dependent ) . 7 . Patient positive serology ( HIV , Hepatitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>